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ABSTRACT 
Objective: To synthesize and evaluate taste-masked ionic liquid (IL) salts of loratadine.  
Methods: In the present work, pharmaceutically active IL salts of loratadine using selected counter-ions were synthesized. The synthesized IL salts 
were characterized using melting point, Ultraviolet (UV) spectroscopy, Fourier Transform Infra-Red (FTIR) spectroscopy, Differential Scanning 
Calorimetry (DSC), and X-ray Diffraction (XRD). These salts were also evaluated for solubility, dissolution, and palatability studies. 
Results: All synthesized IL salts of loratadine exhibited melting points below 100 °C. UV spectral data and FTIR data confirmed the formation of 
new salt forms with selected counter-ions. The absence of sharp melting point peaks during DSC studies revealed the amorphous nature of new salt 
forms. During XRD studies, loratadine-indomethacin IL salt yields completely amorphous compound while the intensity of characteristic peaks of 
loratadine was found to be reduced with other counter-ions. Solubility studies revealed that the solubility of loratadine is reduced from 35.85 
mg/ml to 3.63 mg/ml, 15.39 mg/ml, 5.31 mg/ml, and 3.71 mg/ml in case of IL-1, IL-2, IL-3, and IL-4, respectively. Dissolution studies further 
confirmed this finding. Except for oleate, all the IL salts were found to be palatable by subjects with the score ranging from 2.5 to 2.8, which is the 
standard range for palatability.  
Conclusion: Results obtained in the present work indicated that IL salts of loratadine can be synthesized successfully using selected counter-ions. 
This approach can be used to mask the bitter taste of pure loratadine and thus can be used for the development of drug products intended for 
children. 
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INTRODUCTION 
Ionic liquid (IL) salts are a new class of purely ionic, salts of 
compounds that have very low melting points. Many times they exist 
in the liquid state at room temperature. By the official definition, 
“Ionic liquids (IL) are ionic compounds that are liquid below 100 °C”. 
At room temperature, such compounds appear either like liquids or 
fused or soft solids [1-3]. Although ionic in nature but the properties 
of IL salts differ from typical inorganic salts. In the IL salts, the 
charges are not confined/localized to one particular area in the 
molecule; rather, they are distributed over a large volume. Due to 
this, the intensity of charge in a localized area reduces and crystal 
packing becomes loose. This is the reason for the low melting points 
of IL salts. Typical inorganic salts, on the other hand, have 
symmetrical packing in their crystal structure and charges are well 
localized [4]. These IL salts have additional properties like non-
flammable [1], thermally, mechanically, and electrochemically stable 
[5, 6], etc. Due to such unique properties of IL salts, these are used as 
solvents in synthesis and separation of organic compounds [1, 7-9], 
as thermal fluids [10], lubricants [10], electrolytes [10], electro-
elastic materials [11], etc. 
In pharmaceutical sciences also, ILs are used to facilitate synthesis 
and analysis of active pharmaceutical ingredients (APIs). Some 
researchers have used the concept of IL for synthesizing novel ionic 
salts of existing medicinal compounds to overcome the difficulties 
associated with them [12]. When combined with suitable counter-
active/inactive ions, the IL salts of APIs may yield compounds with 
improved solubility, stability, bioavailability, palatability, and 
therapeutic activity [13]. When IL salts are prepared using two APIs, 
it has dual therapeutic activity and thus forms a very useful 
alternative for fixed-dose combination drugs [14].  
Loratadine is Ethyl-4-(8-chloro-5, 6-dihydrobenzo [1, 2] cyclohepta 
[2,4-b] pyridine-11-ylidene) piperidine-1-carboxylate, second-
generation antihistaminic drug. It is widely prescribed to patients of 
all age groups for the treatment of symptoms of rhinitis and other 
allergies. It is prescribed alone or in combination with nasal 
decongestants, analgesics or anti-inflammatory agents [15]. It is 
available in the form of tablets, chewable tablets, orally 
disintegrating tablets, oral solutions [16], and oral suspensions [17]. 
Being very bitter in nature, patient acceptability of its dispersible, 
orally disintegrating, and liquid dosage forms is very poor [18, 19]. 
In the present work, an attempt has been made to synthesize taste-
masked IL salts of Loratadine to improve its palatability issues. Both 
inactive and active counter-ions were used to synthesize IL salts. 
The IL salts were characterized using melting points, Ultra Violet 
(UV) spectroscopy, Infra-Red (IR) spectroscopy, X-ray 
diffractometry (XRD) and differential scanning calorimetry (DSC). 
The IL salts were also evaluated for their dissolution profile and 
palatability and compared with the existing Loratadine 
hydrochloride salt. 
MATERIALS AND METHODS 
Material 
Loratadine, oleic acid, salicylic acid, indomethacin, and diclofenac 
sodium were gifted generously by Zim Laboratories Ltd., 
Kalmeshwar, Nagpur. All other reagents and solvents used were of 
analytical grade. 
Preparation of IL salts  
Loratadine and selected counter-ion were mixed in the ratio 
mentioned in table 1 by continuous stirring in ethanol in a water 
bath for 10 min at 70-80 °C [20]. The resultant IL salt was collected 
by evaporating solvent at room temperature in airtight vials and 
stored at ambient condition till further characterization and 
evaluation. For convenience, all IL salts were given a code 
mentioned in table 1. 
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Table 1: IL salts of loratadine with selected counter-ions 
Code of IL salts Components (Ratio by weight) 
IL-1 Loratadine: Oleic acid (1:0.5) 
IL-2 Loratadine: Salicylic acid (1:1) 
IL-3 Loratadine: Indomethacin (1:1) 
IL-4 Loratadine: Diclofenac Na (1:1) 
 
Characterization of IL salts 
Melting point 
Melting points of synthesized IL salts were determined using the 
melting point apparatus (Biotec India) and compared with the 
melting point of pure loratadine. One end of a capillary tube was 
sealed using heat and was filled with the sample and the capillary 
tube was then inserted into the melting point chamber and a 
thermometer was inserted into the thermometer chamber of the 
apparatus. The temperature at the onset and after the complete 
melting of the sample was recorded [21].  
UV spectroscopy 
UV spectra of pure loratadine and synthesized IL salts were 
recorded using Shimadzu 1800 (Kyoto, Japan) UV-spectro-
photometer. About10 mg of pure loratadine was accurately weighed 
and dissolved in methanol. The solution was sonicated for 30 min, 
filtered and the spectrum was recorded in the range of 400 nm to 
200 nm in a 1.0 cm cell using methanol as blank. The same 
procedure was repeated for the synthesized IL salts and counter-
ions. The max of each compound was recorded. 
FTIR spectroscopy 
FTIR transmission spectra of pure loratadine and synthesized IL 
salts were recorded using FTIR-8300, Shimadzu, Japan. Samples 
were prepared in KBr disks by means of the hydraulic press at 6-8 
tons pressure [22]. The scanning range was 500 to 4000 cm-1 and 
the resolution was 4 cm-1.  
DSC studies 
Solid-state characterization allows direct insight into the spatial 
relationship between the cation and anion through the elucidation of 
crystal structures and this provides a strong basis from which 
structural features of the ionic liquid can be studied [23]. Both DSC 
and XRD techniques help to understand the changes in the crystal 
structures of the newly synthesized IL salts.  
DSC analysis of pure loratadine and synthesized IL salts were 
performed using DSC-60 plus Shimadzu (Kyoto, Japan). Samples 
were heated in an open aluminum pan at a rate of 5 °C per min-1 in a-
140 °C to 600 °C temperature range, under a nitrogen flow of 40 
ml/min. Current. 
XRD studies 
XRD patterns of pure loratadine and synthesized IL salts were 
recorded on an X-ray diffractometer (PANalytic Spectric Pvt. Ltd., 
Singapore) using Ni-filtered, CuKα radiation, a voltage of 40 kV and a 
25 mA current. The scanning rate employed was 1° per minover the 
2° to 60° diffraction angle (2Ɵ) range. 
Evaluation of IL salts  
Solubility studies  
The solubility of loratadine and synthesized IL salts were determined in 
water. Wherever counter-ion was an active drug, the solubility of 
counter-ion was also determined. The excess of each compound was 
dissolved in distilled water (20 mg in 100 ml ~0.020 % w/v), sonicated 
for 30 min. The solution was then filtered (0.22 µm pore size) and the 
absorbance of each solution was recorded at the respective max using 
Shimadzu 1800 (Kyoto, Japan) UV spectrophotometer.  
Dissolution studies 
In vitro drug release or dissolution study was performed using USP 
apparatus II (Electrolab, Mumbai, India) in 900 ml of 0.1 M HCl as 
dissolution medium. The rotational speed of the paddle was set at 50 
rpm at 37±0.5 °C. Aliquots (10 ml each) were withdrawn at 
predetermined time interval (15 min) for 75 min, sink conditions 
were maintained. The samples were analyzed for drug content using 
double beam UV spectrophotometer (UV 1800 PC, Shimadzu 
Corporation, Kyoto, Japan) at 246.8 nm. 
Palatability evaluation 
Healthy human volunteers of either sex, in the age group of 20-25 y 
were selected (n=6) on the basis of their taste sensitivities. The 
informed consent from these volunteers was obtained prior to the 
studies. The non-tasters and supertasters were rejected. The 
selected panel of volunteers were trained for taste evaluation by 
using solutions with bitterness ranging from tasteless to extremely 
bitter and were asked to score the bitterness on the scale of 0-5. The 
score 5 was assigned to an extremely bitter taste [21]. Each 
volunteer was asked to taste about a pinch of each compound and 
record the bitterness levels as per the scale given in table 4. After 
tasting of every compound, subjects were asked to spit out the 
contents and rinse the mouth thoroughly with purified water. The 
taste scale was validated by testing samples randomly. The washout 
period between testing of two samples was at least 15 min.  
RESULTS AND DISCUSSION 
Melting point  
The melting point of loratadine and synthesized IL salts are 
presented in table 2. When compared with loratadine, the melting 
point of each synthesized IL salt showed a significant reduction in 
melting point. It was observed that upon combining loratadine with 
all other selected ions, the melting point of loratadine was lowered 
from 133 °C to less than 100 °C. All the synthesized IL salts of 
loratadine revealed melting points in the range from 85 °C to 100 °C. 
Further, it was noted that none of the synthesized IL salts showed a 
sharp melting point, which indicated that these synthesized 
compounds were not crystalline in nature. 
 
Table 2: Melting point and ʎ max of pure drugs and their IL salts 
Drugs  Melting points ʎ max Physical Appearance 
Loratadine 133 °C–136 °C±0.2 246.8 nm White Crystalline powder 
Salicylic acid 157 °C–160 °C±1.3 304.2 nm White Crystalline powder 
Indomethacin 160 °C–164 °C±1.25 318.6 nm Pale yellow crystalline powder 
Diclofenac Na 286 °C–289 °C±3 275.6 nm White powder 
IL-1 85 °C–90 °C±1.2 247 nm Pale white powder, soft to touch 
IL2 94 °C–98 °C±2.2 244 nm, 304 nm Pale white powder, soft to touch 
IL3 96 °C–99 °C±2 254 nm, 318 nm Pale yellow powder, soft to touch 
IL4 95 °C–100 °C±1.2 246 nm, 275 nm Pale white powder, soft to touch 
*Data represented as mean±standard deviation [SD], n=3 
UV spectroscopy 
UV spectra and ʎ max of loratadine and synthesized IL salts are 
presented in table 2. From the UV absorption spectra, it is concluded 
that there is not a significant change in the ʎ
(loratadine and IL salts) because of the presence of similar 
chromophores in both the structures. Therefore, the UV spectral 
data confirms that there is no change in the original structure during 
the reaction and only salt formation between the two species has 
occurred. 
FTIR spectroscopy  
FTIR studies were performed for the detection of possible molecular 
interaction between loratadine and counter-
spectra of loratadine and synthesized IL salts are presented in 
Pure loratadine spectra shows aromatic C-H stretch
carboxyl O-H stretch at 2900 cm-1, C=O stretch at 
aromatic C=C stretch at 1560 cm-1, tertiary aromatic amine C
stretch at 1321 cm-1, ether C-O stretch at 1169
stretch at 1082 cm-1 and C-H bending at 714 cm
stretch at 2975 cm-1 of loratadine is retained in all the IL
C=O stretch of carbonyl group at 1699 cm-1of loratadine 
to 1697 cm-1 in IL-1, 1694 cm-1 in IL-2, 1686 cm
cm-1 in IL-4 respectively. This shows the involvement of carbonyl 
oxygen in the salt formation with positively charged nitrogen of 
diclofenac and indomethacin. The tertiary aromatic amine C
stretch at 1321 cm-1of loratadine shifted to 1325 cm
cm-1 in IL-3 and 1304 cm-1 in IL-4 respectively 
formation between loratadine and counter-ions.
1169 cm-1 of loratadine shifted to 1167 cm-1 in IL
2, 1220 cm-1 in IL-3, respectively indicated salt 
loratadine and counter-ions. Aryl chloride stretch at 1082 cm
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-1 of 
loratadine shifted to 1080 cm-1
in IL-3 and unchanged in IL-4 re
loratadine gets associated with 
diclofenac in salt formation. 
between loratadine and counter
formation of IL salts. 
DSC studies 
Thermal analysis by DSC is the primary analytical tool for 
understanding the presence of a new solid phase. DSC thermograms 
of pure loratadine and IL salts are presented in fig. 2. Loratadine 
exhibits a characteristic sharp peak at 134.61 °C and its melting 
range was 133.30 °C to 135.95 °C indicates the crystallin
the drug. DSC thermogram of IL
crystalline loratadine to amorphous oleate salt as revealed by the 
absence of any sharp peak in the thermogram. IL
121.33 °C and melt in the range of 118.95 °C to 134.
the lowering of the melting point of loratadine either due to the new 
salt formation or due to the presence of salicylic acid. The 
thermogram of IL-3 revealed the formation of new amorphous salt 
confirmed by the absence of any distinct melting endotherm. IL
shows two peaks, at 53.34 °C and 132.15 °C. These two peaks do not 
correspond to the melting points of individual components of the 
synthesized salt. The formation of a new compound in the IL
further confirmed by the diffused nature of both of these peaks. The 
IR Spectra and DSC thermographs of the loratadine ionic liquid salts 
indicated that salt formation occurred in the ionic liquid and did not 
result in API degradation.  
Thus, it can be concluded on the basis of DSC studies that attempt to 
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Fig. 3: XRD of (a) Loratadine. (b) IL-1 (Loratadine+Oleic Acid) (c) IL-2 (Loratadine+Salicylic Acid) (d) IL-3 (Loratadine+Indomethacin) (e) 
IL-4 (Loratadine+Diclofenac Na) 
 
XRD studies 
In diffractograms, the peak position (angle of diffraction) is 
indicative of a crystal structure and peak height is a measure of the 
sample crystallinity. The physical state of loratadine in IL salts were 
investigated by XRD, which could provide information on 
crystallinity and crystal orientation. X-ray diffraction pattern of pure 
loratadine and synthesized IL salts are presented in fig. 3. XRD 
analysis was performed to confirm the results of FTIR and DSC 
studies. The X-ray diffraction pattern of loratadine exhibit sharp, 
highly intense and less diffused peaks indicating the crystalline 
nature of the drug. The pure loratadine showed diffraction peaks at 
2Ɵ degree of 19.76, 21.44, 21.20 and 24.10 shows that the drug was 
crystalline in nature. IL-1 shows only peaks like that of loratadine. 
IL-2 shows peaks at 21.29, 23.03, 23.87, 27.44 shows crystalline 
nature. In IL-3 and IL-4, peaks between 20 °-30 ° were broadened; 
indicating conversion of the crystalline structure to amorphous one 
and hypothesis was supported by FTIR and DSC studies. It has been 
reported that to achieve maximum therapeutic efficacy, it is 
important that ILs of API should be in amorphous form. Amorphous 
APIs have higher solubility, higher dissolution rate and reduced 
polymorphism than corresponding crystals [24]. 
The X-ray diffraction pattern of IL salts was simply a 
superimposition of each component with peaks of loratadine. In the 
case of IL salts, diffraction peaks (2Ɵ degree) showed sharp peaks 
with reduced intensity. This suggests that the crystallinity of 
loratadine was reduced in IL salts preparation. 
Solubility studies  
Synthesized IL salts were consisted of loratadine and counter-ions. 
These counter-ions affect the solubility of the resulting salt. The IL 
salts were tested for their solubility in distilled water. The solubility 
profile of loratadine and synthesized IL salts are given in table 3. 
From the solubility studies, it was evident that the solubility of 
synthesized IL salts was decreased in distilled water. Since all the 
selected counter-ions were lipophilic in nature; therefore, the effect 
on solubility in water was as expected. All the IL salts were found to 
have lower water solubility as compared to the pure loratadine. This 
indicates that the IL salts are more lipophilic than the pure 
loratadine. This increase in the lipophilicity of the resulting IL salt 
may increase the membrane permeability, hence, may have the 
potential of faster absorption in the gastrointestinal tract. This can 
be evaluated in future studies. 
 
Table 3: Solubility of pure drugs and synthesized IL salts in water 
Drug *Solubility in water (mg/ml)  IL salts *Solubility in water (mg/ml) 
Loratadine Counter-ion 
Loratadine 35.85±1.5 IL-1 3.63±1.4 ------------- 
Salicylic acid 8.94±1.2 IL-2 15.39±1.2 10.27±1.3 
Indomethacin 7.55±0.2 IL-3 5.31±0.2 3.39±0.2 
Diclofenac Na 15.90±1.23 IL-4 3.71±0.8 4.49±1.1 
 * Data represented as mean±standard deviation [SD], n=3 
 
Dissolution studies 
The dissolution profile of pure loratadine and synthesized IL salts 
are presented in fig. 4. It was evident from the data that the 
percentage drug released decreased in IL-1 due to the extremely 
lipophilic nature of oleic acid whereas in IL-2, IL-3 and IL-4, it was 
nearby or same as loratadine. The results are in agreement with that 
obtained from solubility studies, DSC and XRD. Thus, the in vitro 
dissolution study shows that drug release was less or the same as 
that of loratadine due to extremely low solubility of loratadine. 
The dissolution of IL salts was slow due to physical nature of IL salts, 
which makes aggregate mass when comes in contact with aqueous 
media. Thus decreasing effective surface area available for 
dissolution, hence showed sustained release behaviour. 
IL salts using counter-ions, oleic acid, salicylic acid, indomethacin 
and diclofenac sodium showed slower and lower dissolution as 
compared to loratadine due to high molecular weight or bulky 
nature or may have hindered drug release from IL salts. Hence they 
can be used for sustained release purposes. 
Palatability evaluation 
Palatability evaluations were carried out by the consents of human 
volunteers are presented in table 4 and fig. 5. IL-1 was rated as oily 
and tasteless. Because of the oily taste, the mean score was 3.66  
0.69 and hence was not very much acceptable. IL-2, IL-3 and IL-4 
were rated as palatable by volunteers of the panel. The taste 
masking can be attributed to the reduction in water solubility of the 
synthesized ILs. Due to the lesser solubility, the loratadine IL salts do 
not solubilize when on the tongue and hence cannot interact with 
the taste buds for perceiving the taste. These studies suggested 
utility of IL approach for taste masking of bitter drugs. 
Fig. 4: In vitro 
Table 4: Taste 











 *Data represented as mean±standard deviation [SD], n=
 
Fig. 5: Taste masking evaluation of lorat
CONCLUSION 
It can be concluded from the above studies that the selected counter
ions can form ionic liquids with loratadine as confirmed from the 
change in melting point, as well as from FTIR, DSC
The prepared ILs can effectively mask the bitter tas
as evident from the studies carried out on human volunteers for 
taste evaluation. Thus, the prepared ILs can be used for the 
formulation of the patient-friendly dosage form
solutions, orally disintegrating tablets, etc. IL
indomethacin and diclofenac can be used in 
combinations where both anti-histaminic and 
properties are desired. 
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